212 related articles for article (PubMed ID: 9815596)
21. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
[TBL] [Abstract][Full Text] [Related]
24. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
25. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
27. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2012 Jul; 70(1):151-60. PubMed ID: 22660735
[TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
29. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
Le Garrec D; Gori S; Luo L; Lessard D; Smith DC; Yessine MA; Ranger M; Leroux JC
J Control Release; 2004 Sep; 99(1):83-101. PubMed ID: 15342183
[TBL] [Abstract][Full Text] [Related]
30. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
32. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
34. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
35. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
37. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
38. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
39. Effects of plasma protein binding displacement on the pharmacokinetics, tissue and tumor concentrations and efficacy of brequinar, a highly protein-bound antitumor agent.
Aungst BJ; Blake JA; Rogers NJ; Dusak BA
J Pharmacol Exp Ther; 1990 Apr; 253(1):230-6. PubMed ID: 2329509
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]